Higher-Risk Chronic Myelomonocytic Leukemia Market: Industry Analysis, Pipeline, Epidemiology, Drugs, Companies by DelveInsight | Argenx, Novartis, Kura Oncology, Sensei Biotherapeutics, Takeda,others

May 14 07:46 2021
Higher-Risk Chronic Myelomonocytic Leukemia Market: Industry Analysis, Pipeline, Epidemiology, Drugs, Companies by DelveInsight | Argenx, Novartis, Kura Oncology, Sensei Biotherapeutics, Takeda,others

Higher-Risk Chronic Myelomonocytic Leukemia Market

DelveInsight’s “Higher-Risk Chronic Myelomonocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Higher-Risk Chronic Myelomonocytic Leukemia , historical and forecasted epidemiology as well as the Higher-Risk Chronic Myelomonocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Higher Risk Chronic Myelomonocytic Leukemia Market are:

  • CMML affects approximately 3 out of 100,000 individuals in the United States each year.
  • The risk of CMML increases with age. This disease is rare in those younger than 40, with most cases found in people 60 and older.
  • Median survival of patients with CMML is reported to be approximately 12 to 40 months.
  • Through various secondary studies it can be concluded that overall HR-CMML affects more males than females.
  • The disease incidence rate ranges between 3.5 and 4.1/1 000 000 per year in the United States and in Europe.
  • On an average, patients with CMML demonstrate ~10-15 mutations per kilobase of coding DNA regions, similar to patients with acute myeloid leukemia (AML), but several folds lower than other malignancies such as melanoma and lung cancer.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/higher-risk-chronic-myelomonocytic-leukemia-market

 

Some of Higher Risk Chronic Myelomonocytic Leukemia companies are:

  • Pharmion Corporation
  • Otsuka America Pharmaceutical
  • Argenx
  • Novartis
  • Kura Oncology
  • Sensei Biotherapeutics
  • Takeda
  • Humanigen
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/higher-risk-chronic-myelomonocytic-leukemia-market

 

Chronic Myelomonocytic Leukemia (CMML) is a rare, clonal hematopoietic stem cell disorder characterized by the presence of sustained (>3 months) peripheral blood (PB) monocytosis (≥1 × 109/L; monocytes ≥10% of white blood cell count) along with dysplastic features in the bone marrow (BM). CMML has some similarities with a condition called myelodysplastic syndrome (MDS) and some resemblance to a group of conditions called myeloproliferative neoplasms (MPN). It is classified as being a mixture of these two conditions.

CMML shares clinical and biological features with MDS, including cytopenia and bone marrow failure, risk of progression to AML, and overlapping, recurring, cytogenetic abnormalities.

CMML can be further subdivided into two categories depending on the number of blasts found in the peripheral blood and bone marrow, CMML-1 with less than 5% blasts in peripheral blood and less than 10% in bone marrow, and CMML-2 with 5 to 19% blasts in peripheral blood and/or 10 and 19% in the bone marrow.

 

Some of Higher Risk Chronic Myelomonocytic Leukemia therapies are:

  • Vidaza
  • Dacogen
  • Cusatuzumab
  • MBG453
  • Tipifarnib
  • SNS-301
  • Pevonedistat
  • Lenzilumab
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/higher-risk-chronic-myelomonocytic-leukemia-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Higher-Risk Chronic Myelomonocytic Leukemia

3. Competitive Intelligence Analysis for Higher-Risk Chronic Myelomonocytic Leukemia

4. Higher-Risk Chronic Myelomonocytic Leukemia : Market Overview at a Glance

5. Higher-Risk Chronic Myelomonocytic Leukemia : Disease Background and Overview

6. Patient Journey

7. Higher-Risk Chronic Myelomonocytic Leukemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Higher-Risk Chronic Myelomonocytic Leukemia Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Higher-Risk Chronic Myelomonocytic Leukemia : Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Higher-Risk Chronic Myelomonocytic Leukemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/higher-risk-chronic-myelomonocytic-leukemia-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/higher-risk-chronic-myelomonocytic-leukemia-market

  Categories: